With 17 votes to zero, the “Corona” vaccine for children obtains approval

0
20


Experts: Vaccine benefits vastly outweigh all risks


Advisers to the US Food and Drug Administration (FDA) have voted to approve the Pfizer COVID-19 vaccine for children 5 to 11 years old.

The vote of the committee of experts in the authority ended late yesterday evening, Tuesday (11 pm Riyadh time) in favor of granting the vaccine with 17 votes to zero, with one vote abstaining, and experts confirmed that the benefits of the vaccine greatly outweigh any risks.

A source from the US Food and Drug Administration indicated that no date has been set for the launch of the children’s vaccination campaign at the present time, but he expected that the campaign will be launched in the United States at the beginning of next November, and several countries will follow suit as well.

The team discussed the risk of developing myocarditis, an inflammatory condition of the heart that was found in a small number of young people and adolescents who received some types of vaccines, but these cases were not detected in the children’s study although it was small and limited to discovering the potential risks.

It is expected that the children’s vaccine will be deployed in schools and children’s recreation areas as well as pharmacies and other health facilities.

By 17 votes to zero, the “Corona” vaccine for children receives final approval

previously

Advisers to the US Food and Drug Administration (FDA) have voted to approve the Pfizer COVID-19 vaccine for children 5 to 11 years old.

The vote of the committee of experts in the authority ended late yesterday evening (11 pm Riyadh time) in favor of granting the vaccine by 17 votes to zero, with one vote abstaining, and experts confirmed that the benefits of the vaccine greatly outweigh any risks.

A source from the US Food and Drug Administration indicated that no date has been set for the launch of the children’s vaccination campaign at the present time, but he expected that the campaign would be launched in the United States at the beginning of next November, and several countries would follow suit as well.

The team discussed the risk of developing myocarditis, an inflammatory condition of the heart that was found in a small number of young people and adolescents who received some types of vaccines, but these cases were not detected in the children’s study although it was small and limited to discovering the potential risks.

It is expected that the children’s vaccine will be deployed in schools and children’s recreation areas as well as pharmacies and other health facilities.

October 27, 2021 – Rabi` al-Awwal 21, 1443

12:59 AM

Last update
October 27, 2021 – Rabi` al-Awwal 21, 1443

03:17 AM


Experts: Vaccine benefits vastly outweigh all risks

Advisers to the US Food and Drug Administration (FDA) have voted to approve the Pfizer COVID-19 vaccine for children 5 to 11 years old.

The vote of the committee of experts in the authority ended late yesterday evening (11 pm Riyadh time) in favor of granting the vaccine by 17 votes to zero, with one vote abstaining, and experts confirmed that the benefits of the vaccine greatly outweigh any risks.

A source from the US Food and Drug Administration indicated that no date has been set for the launch of the children’s vaccination campaign at the present time, but he expected that the campaign would be launched in the United States at the beginning of next November, and several countries would follow suit as well.

The team discussed the risk of developing myocarditis, an inflammatory condition of the heart that was found in a small number of young people and adolescents who received some types of vaccines, but these cases were not detected in the children’s study although it was small and limited to discovering the potential risks.

It is expected that the children’s vaccine will be deployed in schools and children’s recreation areas as well as pharmacies and other health facilities.





LEAVE A REPLY

Please enter your comment!
Please enter your name here